A new study combining two powerful, non-invasive cancer treatments offers new hope for less harmful breast cancer therapy.  

Dr. Michael C. Oldham's innovative gene coexpression analysis methods have transformed our understanding of brain cell diversity. His work spans from mapping cellular signatures in healthy brains to identifying therapeutic targets in gliomas, while addressing critical challenges in research reproducibility.

Dr. Jin Wang from University of Chinese Academy of Sciences/ State University of New York at Stony Brook and Dr. Xiaona Fang from Northeast Normal University published an article titled “Identifying early warning signals of cancer formation” in the journal Quantitative Biology. Using theories of nonequilibrium potential landscape and steady-state probability flux, and indicators such as entropy production rate and mean flux derived from time-series gene expression data, they identified early warning signals during gastric cancer development, providing theoretical basis for early diagnosis.

Landmark research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some promising cancer treatments are causing serious side effects, and offers a roadmap for designing safer, more targeted therapies. 

The WEHI-led discovery, published in Science, has uncovered a critical new role for MCL-1, revealing it not only prevents cell death but also provides cells with the energy they need to function.  

The findings reshape our understanding of how cells survive and thrive, with implications for both cancer treatment and developmental biology. 

Rice’s Lei Li wins NSF CAREER Award to develop a new generation of wearable medical imaging technology capable of visualizing deep tissue function in real time.

A pairing of two experimental drugs inhibits tumor growth and blocks drug-induced resistance in ovarian cancer, according to a preclinical study led by Weill Cornell Medicine investigators. The research reveals a promising strategy against this hard-to-treat malignancy, and more generally demonstrates a powerful new approach for the identification of effective regimens to treat genetically diverse cancers.

Researchers from the Institute of Biophysics of the Chinese Academy of Sciences, the Grossman School of Medicine at New York University, and the School of Medicine at Zhejiang University have systematically demonstrated that LAG-3 inhibits T cell activity by positioning itself in close proximity to the T cell receptor (TCR) complex, rather than by simply binding to a ligand.